

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for treating amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or suppressing the progression thereof, which comprises administering to a patient in need thereof as an active ingredient 3-methyl-1-phenyl-2-pyrazoline-5-one, or a physiologically acceptable salt thereof, ~~or a hydrate thereof~~, under the condition that a combination of a drug administration period of ~~1 day to about~~ 14 days and a drug holiday period of ~~1 day to about~~ 14 days is repeated during the period for treating the disease or suppressing the progression of the disease.

2-6. (Cancelled)

7. (Currently Amended) ~~The method of claim 1, wherein A method for treating amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or suppressing the progression thereof, which comprises administering to a patient in need thereof as an active ingredient 3-methyl-1-phenyl-2-pyrazoline-5-one or a physiologically acceptable salt thereof, under the condition that~~ a course consisting of an initial drug administration period of 14 days and a drug holiday period of 14 days is provided, followed by repetitions of the following combination of periods:

drug administration period: 5 days per week for 2 weeks; and
drug holiday period: 14 days.

8. (Currently Amended) The method of claim 1, wherein the daily dose contains about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one ~~as an active ingredient, or about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.~~

9. (Currently Amended) The method of claim 1, wherein the daily dose contains about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one ~~as an active ingredient, or about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.~~

10. (Previously Presented) The method of claim 1, wherein the administration is carried out once daily.

11. (Previously Presented) The method of claim 1, wherein the administration is a continuous administration.

12. (Previously Presented) The method of claim 11, wherein the continuous administration is intravenous infusion administration.

13. (Currently Amended) The method of claim 12, wherein the administration rate in the intravenous infusion administration is about 0.5 to 1 mg/minute with respect to 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient ~~or 3-methyl-1-phenyl-2-pyrazoline-5-one contained in an active ingredient.~~

14. (Cancelled)

15. (Previously Presented) The method of claim 1, wherein the symptoms caused by amyotrophic lateral sclerosis are decreased respiratory function, voice and speech disorders, dysphagia, or upper and lower extremity motor disorders.

16. (Previously Presented) The method of claim 1, wherein the treatment of amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or the suppression of the progression thereof is a suppression of decrease in respiratory function in amyotrophic lateral sclerosis.

17-32. (Cancelled)

33. (New) The method of claim 7, wherein the daily dose contains about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

34. (New) The method of claim 7, wherein the daily dose contains about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

35. (New) The method of claim 7, wherein the administration is carried out once daily.

36. (New) The method of claim 7, wherein the administration is a continuous administration.

37. (New) The method of claim 36, wherein the continuous administration is intravenous infusion administration.

38. (New) The method of claim 37, wherein the administration rate in the intravenous infusion administration is about 0.5 to 1 mg/minute with respect to 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient.

39. (New) The method of claim 7, wherein the symptoms caused by amyotrophic lateral sclerosis are decreased respiratory function, voice and speech disorders, dysphagia, or upper and lower extremity motor disorders.

40. (New) The method of claim 7, wherein the treatment of amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or the suppression of the progression thereof is a suppression of decrease in respiratory function in amyotrophic lateral sclerosis.